



SDI Review Form 1.6

Journal Name:	International Journal of Medical and Pharmaceutical Case Reports
Manuscript Number:	Ms_IJMPCR_26538
Title of the Manuscript:	Novel Therapy May Be the First Line Treatment for Multiple Myeloma but Should Not Be the Last Word: Two Cases Illustrated
Type of the Article	Case study

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	This case study can be beneficial for medical science, but I want to suggest some revisions.	
Minor REVISION comments	<ol style="list-style-type: none"> 1) Especially, Case 1 is too long. Absolutely you must shorten this section. 2) Abstract section " immunomodulatory drugs and proteasome inhibitors" you must explain which drugs which group. You can add a new sentence for explain this 3) Figure 1 and Figure 2 are too mix. You must simply and increase image quality. 4) For explain therapy line new table can be added every cases. 	
Optional/General comments		

Reviewer Details:

Name:	<i>Ilhami Berber</i>
Department, University & Country	<i>Malatya State Hospital, Turkey</i>